Drug
Insulin Degludec 100 Unt Tresiba
Insulin Degludec 100 Unt Tresiba: highest development phase Post-Market, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| Insulin Degludec 100 UNT/ML [Tresiba] NCT03244241 | Post-Market | Type 2 Diabetes Mellitus |
Latest
No recent events.
Follow Insulin Degludec 100 Unt Tresiba on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.